Human BCL9 peptide (ab37304)
Key features and details
- Purity: > 90% HPLC
- Suitable for: Blocking, WB
製品の詳細
-
製品名
Human BCL9 peptide
BCL9 タンパク質・ペプチド 製品一覧 -
精製度
> 90 % HPLC. -
Animal free
No -
由来
Synthetic -
-
生物種
Human
-
関連製品
-
Corresponding Antibody
特性
Our Abpromise guarantee covers the use of ab37304 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
-
アプリケーション
Blocking - Blocking peptide for Anti-BCL9 antibody (ab37305)
Western blot
-
製品の状態
Liquid -
備考
- First try to dissolve a small amount of peptide in either water or buffer. The more charged residues on a peptide, the more soluble it is in aqueous solutions.
- If the peptide doesn’t dissolve try an organic solvent e.g. DMSO, then dilute using water or buffer.
- Consider that any solvent used must be compatible with your assay. If a peptide does not dissolve and you need to recover it, lyophilise to remove the solvent.
- Gentle warming and sonication can effectively aid peptide solubilisation. If the solution is cloudy or has gelled the peptide may be in suspension rather than solubilised.
- Peptides containing cysteine are easily oxidised, so should be prepared in solution just prior to use. -
Concentration information loading...
前処理および保存
-
保存方法および安定性
Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
Information available upon request.
関連情報
-
別名
- B-cell CLL/lymphoma 9
- BCL 9
- Legless homolog
- LGS
-
関連性
BCL9 is involved in signal transduction through the Wnt pathway. It promotes beta-catenin's transcriptional activity. BCL9 is associated with B-cell acute lymphoblastic leukemia. The overexpression of BCL9 may be of pathogenic significance in B-cell malignancies (referenced from swissprot and entrez gene). -
細胞内局在
Nuclear
画像
-
Blocking - Human BCL9 peptide (ab37304)Image from Takada K et al., Sci Transl Med. 2012 Aug 22;4(148):148ra117. doi: 10.1126/scitranslmed.3003808.; Fig S1.; Sci Transl Med 22 August 2012: Vol. 4, Issue 148, p. 148ra117.BCL9 staining in Human colorectal cancer tissue, blocked with ab37304.
Left panel: ab37305 - BCL9 antibody alone. Right panel: BCL9 antibody + ab37304 - BCL9 peptide.
プロトコール
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
データシートおよび資料
-
Datasheet download
参考文献 (2)
ab37304 は 2 報の論文で使用されています。
- Takada K et al. Targeted disruption of the BCL9/ß-catenin complex inhibits oncogenic Wnt signaling. Sci Transl Med 4:148ra117 (2012). Blocking ; Human . PubMed: 22914623
- Mani M et al. BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells. Cancer Res 69:7577-86 (2009). WB . PubMed: 19738061
